Interleukin (IL)-6 is involved in the maintenance and progression of several diseases such as multiple myeloma, rheumatoid arthritis, or osteoporosis. The present work aims at the development of an IL-6 inhibitor for the use in anti-cytokine therapies. The IL-6 receptor is composed of two different subunits, an alpha-subunit (IL-6Ralpha) that binds IL-6 with low affinity and a beta-subunit (gp130) that binds the IL-6.
View Article and Find Full Text PDFInterleukin (IL)-6-type cytokines are multifunctional proteins involved in cardiac hypertrophy and myocardial protection. Recent studies, performed on animal models, report the production of these cytokines by heart. The aim of this study was to analyse the capacity of myocytes and fibroblasts isolated from human atrium to secrete IL-6, leukaemia inhibitory factor (LIF), cardiotrophin-1 (CT-1), IL-11, oncostatin M (OSM), ciliary neurotrophic factor (CNTF) and the soluble receptor subunits sIL-6R and sgp130 during primary culture.
View Article and Find Full Text PDFIntroduction: Using an adult rat ventricular culture model and whole-cell patch-clamp technique, we investigated whether the nifedipine-resistant calcium current observed at the neonatal stage but not at the adult stage could be reobserved under dedifferentiating conditions.
Methods And Results: Application of 2 microM nifedipine totally inhibited the inward calcium current (carried by 5 mM Ba2+) in freshly isolated cells from adult rat heart, but it failed to block it completely when cells are cultured for 8 to 12 days. Dose-response curves of nifedipine in the range from 2 to 50 microM showed a residual current that represented, in the presence of 2 microM nifedipine, 16.